Wilmington Savings Fund Society FSB Raises Stake in Medpace Holdings, Inc. (NASDAQ:MEDP)

Wilmington Savings Fund Society FSB lifted its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 46.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 767 shares of the company’s stock after acquiring an additional 242 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Medpace were worth $255,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Pallas Capital Advisors LLC raised its stake in Medpace by 179.7% during the fourth quarter. Pallas Capital Advisors LLC now owns 3,270 shares of the company’s stock worth $1,086,000 after purchasing an additional 2,101 shares during the period. Baillie Gifford & Co. raised its position in shares of Medpace by 175.6% during the 3rd quarter. Baillie Gifford & Co. now owns 14,876 shares of the company’s stock valued at $4,966,000 after buying an additional 9,478 shares during the period. Barclays PLC lifted its holdings in Medpace by 71.9% in the third quarter. Barclays PLC now owns 19,781 shares of the company’s stock valued at $6,603,000 after acquiring an additional 8,275 shares during the last quarter. Oppenheimer Asset Management Inc. grew its position in Medpace by 6.3% in the third quarter. Oppenheimer Asset Management Inc. now owns 45,473 shares of the company’s stock worth $15,179,000 after acquiring an additional 2,675 shares during the period. Finally, CWA Asset Management Group LLC acquired a new stake in Medpace during the third quarter worth $1,306,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of MEDP stock opened at $327.86 on Wednesday. The stock has a market capitalization of $10.19 billion, a P/E ratio of 28.71, a price-to-earnings-growth ratio of 1.85 and a beta of 1.36. Medpace Holdings, Inc. has a fifty-two week low of $302.01 and a fifty-two week high of $459.77. The company has a 50 day moving average price of $344.13 and a 200 day moving average price of $349.34.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 50.87% and a net margin of 17.66%. On average, research analysts forecast that Medpace Holdings, Inc. will post 11.93 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities research analysts have commented on the company. William Blair restated an “outperform” rating on shares of Medpace in a research report on Tuesday, October 22nd. TD Cowen reduced their price objective on shares of Medpace from $413.00 to $372.00 and set a “buy” rating on the stock in a report on Wednesday, October 23rd. Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Finally, Baird R W downgraded shares of Medpace from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 23rd. Seven investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, Medpace currently has an average rating of “Hold” and an average target price of $381.44.

Medpace Profile

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.